C8218
Monoclonal Anti-Cdk4 antibody produced in mouse
clone DCS-31, ascites fluid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Pricing and availability is not currently available.
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
DCS-31, monoclonal
mol wt
antigen 33 kDa
contains
15 mM sodium azide
species reactivity
rat, mouse, human
technique(s)
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:1,000 using a cultured human tumor cell line extract
isotype
IgG2a
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CDK4(1019)
mouse ... Cdk4(12567)
rat ... Cdk4(94201)
General description
Cdk4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen (PCNA) and a protein inhibitor, p21Cip1. Cdk4 associates separately with p16, particularly in cells lacking a functional retinoblastoma protein.
Monoclonal Anti-Cdk4 (mouse IgG2a isotype) is derived from the DCS-31 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Cyclin-dependent kinase 4 is localized in human chromosome 12q14.1.
Specificity
The antibody reacts specifically with Cdk4 and does not recognize other Cdk types.
Immunogen
recombinant human Cdk4 protein
Application
Biochem/physiol Actions
In association with cyclins, cyclin-dependent kinases (CDKs) forms active kinase complexes which is responsible for regulating cell cycle progression in eukaryotic cells. Within the complexes, the CDKs serves a catalytic protein kinase activity. This catalytic activity is regulated by two mechanisms: protein phosphorylation and association of regulatory subunits.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Adam Z Oskowitz et al.
The international journal of biochemistry & cell biology, 43(11), 1563-1572 (2011-07-29)
Recently we demonstrated that the miRNA regulate human mesenchymal stem cells (hMSCs) differentiation. To determine the role of the miRNA pathway in hMSCs proliferation, Drosha and Dicer knockdown hMSCs were generated using a lentiviral based tetracycline inducible shRNA. hMSCs with
Therese M Becker et al.
International journal of cancer, 117(4), 569-573 (2005-06-10)
Melanoma-associated germline mutations affecting the tumor suppressor and cyclin-dependent kinase (CDK) inhibitor, CDKN2A/p16INK4a, have been identified in over 100 melanoma-prone families worldwide. To predict the melanoma risk for carriers of specific mutations, mutant p16INK4a can be tested in biochemical and
J Pines et al.
The Journal of cell biology, 115(1), 1-17 (1991-10-01)
We have used immunofluorescence staining to study the subcellular distribution of cyclin A and B1 during the somatic cell cycle. In both primary human fibroblasts and in epithelial tumor cells, we find that cyclin A is predominantly nuclear from S
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon
Italiano A, et al.
International Journal of Cancer. Journal International Du Cancer, 122(10), 2233-2241 (2008)
V Cecchinato et al.
Leukemia research, 32(5), 791-797 (2007-10-30)
T acute lymphoblastic leukemia cell lines treated with hexamethylene bisacetamide (HMBA) undergo a delay in cell cycle progression and increase susceptibility to apoptosis, although they never overcome the differentiation block. In accordance with changes in cell cycle and apoptosis, transitory
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
